Contribution of protein A step towards cost of goods for continuous production of monoclonal antibody therapeutics
- 1 February 2021
- journal article
- research article
- Published by Wiley in Journal of Chemical Technology & Biotechnology
- Vol. 97 (9) , 2420-2433
Abstract
BACKGROUND: Monoclonal antibodies (mAbs) presently dominate the biotherapeutic market. However, biotherapeutics in general, and mAbs in particular, are expensive therapies and outside the realm of affordability for most of the world. In an attempt to lower their cost of manufacturing, a novel in‐house non‐protein A continuous platform has recently been reported for mAb purification. In this paper, we perform an in‐depth evaluation of the process economics to assess the impact of removing the protein A step on the cost of goods (COGs).RESULTS: The non‐protein A platform was found to result in significant savings in COGs at about 23% when comparing both platforms in batch mode. Conversion of the non‐protein A platform from batch to continuous mode led to a further increase in these savings with about 39% gains in COGs over the conventional protein A platform.CONCLUSIONS: The non‐protein A purification platform offers a viable alternative to the standard protein A platform and can be considered when setting up a new facility. The continuous non‐protein A platform can especially be considered given the flexibility of the setup and the utility at both small and large scales. © 2021 Society of Chemical IndustryKeywords
Funding Information
- Department of Biotechnology, Government of West Bengal (BT/COE/34/SP15097/2015)
This publication has 32 references indexed in Scilit:
- Cost evaluation of antibody production processes in different operation modesChemical Engineering Science, 2016
- A new, integrated, continuous purification process template for monoclonal antibodies: Process modeling and cost of goods studiesJournal of Biotechnology, 2015
- Single-use disposable technologies for biopharmaceutical manufacturingTrends in Biotechnology, 2013
- Recovery and purification process development for monoclonal antibody productionmAbs, 2010
- The Cost Burden of Trastuzumab and Bevacizumab Therapy for Solid Tumours in CanadaCurrent Oncology, 2008
- Very Large Scale Monoclonal Antibody Purification: The Case for Conventional Unit OperationsBiotechnology Progress, 2007
- Protein A chromatography for antibody purificationJournal of Chromatography B, 2007
- Economic aspects of commercial manufacture of biopharmaceuticalsJournal of Biotechnology, 2004
- Factorial screening of antibody purification processes using three chromatography steps without protein AJournal of Chromatography A, 2004
- Expanded bed adsorption in the purification of monoclonal antibodies: a comparison of process alternativesBioseparation, 2001